TY - JOUR
T1 - Synthesis of 4-(Carbonyloxyphenyl)-1,4-dihydropyridines as potential antihypertensive agents
AU - Bansal, R.
AU - Narang, G.
AU - Calle, C.
AU - Carron, R.
AU - Pemberton, K.
AU - Harvey, A.L.
PY - 2013/2/1
Y1 - 2013/2/1
N2 - Preclinical Research A series of novel symmetric and asymmetric 4-(carbonyloxyphenyl)-1,4-dihydropyridines (DHPs) was synthesized and evaluated for calcium channel blocking, vasodilatory and antihypertensive properties. Some of these new DHPs displayed potent calcium channel blocking and good vasodilatory activities. Heart rate remained relatively constant in comparison with blood pressure changes in the case of these newly synthesized compounds, thereby decreasing the probability of reflex tachycardia, a major side effect of nifedipine. The most potent compound, ethyl methyl 4-(3- isopropylcarbonyloxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (14c) exhibited antihypertensive activity comparable with the standard drug - nifedipine.
AB - Preclinical Research A series of novel symmetric and asymmetric 4-(carbonyloxyphenyl)-1,4-dihydropyridines (DHPs) was synthesized and evaluated for calcium channel blocking, vasodilatory and antihypertensive properties. Some of these new DHPs displayed potent calcium channel blocking and good vasodilatory activities. Heart rate remained relatively constant in comparison with blood pressure changes in the case of these newly synthesized compounds, thereby decreasing the probability of reflex tachycardia, a major side effect of nifedipine. The most potent compound, ethyl methyl 4-(3- isopropylcarbonyloxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (14c) exhibited antihypertensive activity comparable with the standard drug - nifedipine.
KW - synthesis
KW - 4-(Carbonyloxyphenyl)-1,4-dihydropyridines
KW - antihypertensive agents
UR - http://www.scopus.com/inward/record.url?scp=84874500054&partnerID=8YFLogxK
U2 - 10.1002/ddr.21056
DO - 10.1002/ddr.21056
M3 - Article
AN - SCOPUS:84874500054
SN - 0272-4391
VL - 74
SP - 50
EP - 61
JO - Drug Development Research
JF - Drug Development Research
IS - 1
ER -